Table 2.
Baseline characteristics of all patients and of patients in groups 1 and 2
| All included patients | Group 1 (12 (± 2) weeks after prosthesis implantation) | Group 2 (12 (± 2) months after prosthesis implantation) | p value*** | |
|---|---|---|---|---|
| Number of patients | 20 | 10 | 10 | |
| Age, median [IQR], years | 64[60-71] | 64[60-70] | 62[59-73] | .38 |
| Gender, n(%) | 1 | |||
| Male | 14(70) | 7(70) | 7(70) | |
| Female | 6(30) | 3(30) | 3(30) | |
| BMI, median [IQR], kg·m−2 | 26[23-29] | 24[23-28] | 28[24-31] | .12 |
| Days between surgery and PET/CT, median [IQR], days | 218[90-374] | 91[88-95] | 373[358-414] | <.01 |
| Laboratory results* | ||||
| Serum levels of leucocytes × 109/L, median [IQR] | 10.8 [8.9-12.9] | 10.6 [9.8-13.6] | 10.8 [8.5-12.8] | .58 |
| Serum levels of creatinine µmol·L−1, median [IQR] | 82 [62-91] | 77 [58-105] | 86 [67-90] | .8 |
| Medical history, n(%) | ||||
| Hypertension | 2 (10) | 1 (10) | 1 (10) | 1 |
| Atrial fibrillation | 4 (20) | 2 (20) | 2 (20) | 1 |
| Heart failure | 0 (0) | 0 (0) | 0 (0) | NA |
| Myocardial infarction | 1 (5) | 1 (10) | 0 (0) | .31 |
| Prior thoracic surgery | 0 (0) | 0 (0) | 0 (0) | NA |
| Procedure | .33 | |||
| Bentall | 14 (70) | 6 (60) | 8 (80) | |
| AVR+SCAR | 6 (30) | 4 (40) | 2 (20) | |
| PHV type, n(%) | ||||
| Mechanical | 11 (55) | 4 (40) | 7 (70) | .18 |
| Biological | 9 (45) | 6 (60) | 3 (30) | |
| Valve manufacturer, n(%) | ||||
| St. Jude | 11 (55) | 4 (40) | 7 (70) | .18 |
| Perimount | 9 (45) | 6 (60) | 3 (30) | |
| Valve size median [IQR] (mm) | 26 [23-27] | 26 [23-27] | 26 [23-28] | .91 |
| Aorta prosthetic size median [IQR] (mm) | 28 [26-30] | 29 [27-30] | 28 [26-29] | .22 |
| Surgery, n(%) | ||||
| Concomitant CABG | 17 (85) | 8 (80) | 9 (90) | .53 |
| Other concomitant procedure** | 9 (45) | 6 (60) | 3 (30) | .37 |
| Use of surgical adhesives | 0 (0) | 0 (0) | 0 (0) | NA |
PHV, prosthetic heart valve; AVR, aortic valve replacement; BMI, Body Mass Index; PET/CT, Positron Emission Tomography with computed tomography; SCAR, supracoronary aortic replacement; CABG, coronary artery bypass graft; IQR, interquartile range; SD, standard deviation
*Serum Leucocytes and Creatinine levels were measured as part of clinical practice ±5 days after surgery
**Nine patients underwent a concomitant procedure with the aortic PHV implantation containing two patients with a left atrial appendage amputation and pulmonary vein isolation procedure, seven patients with a hemiarch replacement
***Statistical difference between the two groups 1 and 2